|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dela Cruz CS, Tanoue LT and Matthay RA:
Lung cancer: Epidemiology, etiology, and prevention. Clin Chest
Med. 32:605–644. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tas F, Ciftci R, Kilic L and Karabulut S:
Age is a prognostic factor affecting survival in lung cancer
patients. Oncol Lett. 6:1507–1513. 2013.PubMed/NCBI
|
|
5
|
Wainer Z, Wright GM, Gough K, Daniels MG,
Choong P, Conron M, Russell PA, Alam NZ, Ball D and Solomon B:
Impact of sex on prognostic host factors in surgical patients with
lung cancer. ANZ J Surg. doi: 10.1111/ans.13728.
|
|
6
|
Yoshino I and Maehara Y: Impact of smoking
status on the biological behavior of lung cancer. Surg Today.
37:725–734. 2007. View Article : Google Scholar
|
|
7
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM classification of malignant tumours. 7th edition.
Wiley-Blackwell; 2009
|
|
8
|
Greenberg AK and Lee MS: Biomarkers for
lung cancer: Clinical uses. Curr Opin Pulm Med. 13:249–255. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yoon HM, Ryu KW, Nam BH, Cho SJ, Park SR,
Lee JY, Lee JH, Kook MC, Choi IJ and Kim YW: Is the new seventh
AJCC/UICC staging system appropriate for patients with gastric
cancer? J Am Co Surg. 214:88–96. 2012. View Article : Google Scholar
|
|
10
|
Balkwill F and Mantovani A: Inflammation
and cancer: Back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Elinav E, Nowarski R, Thaiss CA, Hu B, Jin
C and Flavell RA: Inflammation-induced cancer: Crosstalk between
tumours, immune cells and microorganisms. Nat Rev Cancer.
13:759–771. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar
|
|
13
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kumar R, Geuna E, Michalarea V,
Guardascione M, Naumann U, Lorente D, Kaye SB and de Bono JS: The
neutrophil-lymphocyte ratio and its utilisation for the management
of cancer patients in early clinical trials. Br J Cancer.
112:1157–1165. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Guthrie GJ, Charles KA, Roxburgh CS,
Horgan PG, McMillan DC and Clarke SJ: The systemic
inflammation-based neutrophil-lymphocyte ratio: Experience in
patients with cancer. Crit Rev Oncol Hematol. 88:218–230. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tierney JF, Stewart LA, Ghersi D, Burdett
S and Sydes MR: Practical methods for incorporating summary
time-to-event data into meta-analysis. Trials. 8:162007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sarraf KM, Belcher E, Raevsky E, Nicholson
AG, Goldstraw P and Lim E: Neutrophil/lymphocyte ratio and its
association with survival after complete resection in non-small
cell lung cancer. J Thorac Cardiovasc Surg. 137:425–428. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Teramukai S, Kitano T, Kishida Y, Kawahara
M, Kubota K, Komuta K, Minato K, Mio T, Fujita Y, Yonei T, et al:
Pretreatment neutrophil count as an independent prognostic factor
in advanced non-small-cell lung cancer: An analysis of Japan
Multinational Trial Organisation LC00-03. Eur J Cancer.
45:1950–1958. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tomita M, Shimizu T, Ayabe T, Yonei A and
Onitsuka T: Preoperative neutrophil to lymphocyte ratio as a
prognostic predictor after curative resection for non-small cell
lung cancer. Anticancer Res. 31:2995–2998. 2011.PubMed/NCBI
|
|
20
|
Cedrés S, Torrejon D, Martinez A, Martinez
P, Navarro A, Zamora E, Mulet-Margalef N and Felip E: Neutrophil to
lymphocyte ratio (NLR) as an indicator of poor prognosis in stage
IV non-small cell lung cancer. Clin Transl Oncol. 14:864–869. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lee Y, Kim SH, Han JY, Kim HT, Yun T and
Lee JS: Early neutrophil-to-lymphocyte ratio reduction as a
surrogate marker of prognosis in never smokers with advanced lung
adenocarcinoma receiving gefitinib or standard chemotherapy as
first-line therapy. J Cancer Res Clin Oncol. 138:2009–2016. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Botta C, Barbieri V, Ciliberto D, Rossi A,
Rocco D, Addeo R, Staropoli N, Pastina P, Marvaso G, Martellucci I,
et al: Systemic inflammatory status at baseline predicts
bevacizumab benefit in advanced non-small cell lung cancer
patients. Cancer Bio Ther. 14:469–475. 2013. View Article : Google Scholar
|
|
23
|
Unal D, Eroglu C, Kurtul N, Oguz A and
Tasdemir A: Are neutrophil/lymphocyte and platelet/lymphocyte rates
in patients with non-small cell lung cancer associated with
treatment response and prognosis? Asian Pac J Cancer Prev.
14:5237–5242. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yao Y, Yuan D, Liu H, Gu X and Song Y:
Pretreatment neutrophil to lymphocyte ratio is associated with
response to therapy and prognosis of advanced non-small cell lung
cancer patients treated with first-line platinum-based
chemotherapy. Cancer Immunol Immunother. 62:471–479. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kang MH, Go SI, Song HN, Lee A, Kim SH,
Kang JH, Jeong BK, Kang KM, Ling H and Lee GW: The prognostic
impact of the neutrophil-to-lymphocyte ratio in patients with
small-cell lung cancer. Br J Cancer. 111:452–460. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pinato DJ, Shiner RJ, Seckl MJ, Stebbing
J, Sharma R and Mauri FA: Prognostic performance of
inflammation-based prognostic indices in primary operable non-small
cell lung cancer. Br J Cancer. 110:1930–1935. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang T, Jiang Y, Qu X, Shen H, Liu Q and
Du J: Evaluation of preoperative hematologic markers as prognostic
factors and establishment of novel risk stratification in resected
pN0 non-small-cell lung cancer. PLoS One. 9:e1114942014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Choi JE, Villarreal J, Lasala J,
Gottumukkala V, Mehran RJ, Rice D, Yu J, Feng L and Cata JP:
Perioperative neutrophil: Lymphocyte ratio and postoperative NSAID
use as predictors of survival after lung cancer surgery: A
retrospective study. Cancer Med. 4:825–833. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mitchell PL, Thatcher N, Socinski MA,
Wasilewska-Tesluk E, Horwood K, Szczesna A, Martín C, Ragulin Y,
Zukin M, Helwig C, et al: Tecemotide in unresectable stage III
non-small-cell lung cancer in the phase III START study: Updated
overall survival and biomarker analyses. Ann Oncol. 26:1134–1142.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shao N and Cai Q: High pretreatment
neutrophil-lymphocyte ratio predicts recurrence and poor prognosis
for combined small cell lung cancer. Clin Transl Oncol. 17:772–778.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shimizu K, Okita R, Saisho S, Maeda A,
Nojima Y and Nakata M: Preoperative neutrophil/lymphocyte ratio and
prognostic nutritional index predict survival in patients with
non-small cell lung cancer. World J Surg Oncol. 13:2912015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Takahashi Y, Horio H, Hato T, Harada M,
Matsutani N, Morita S and Kawamura M: Prognostic significance of
preoperative Neutrophil-Lymphocyte ratios in patients with Stage I
non-small cell lung cancer after complete resection. Ann Surg
Oncol. 22 Suppl 3:S1324–S1331. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang H, Zhang L, Zhu K, Shi B, Yin Y, Zhu
J, Yue D, Zhang B and Wang C: Prognostic significance of
combination of preoperative platelet count and
Neutrophil-Lymphocyte ratio (COP-NLR) in patients with non-small
cell lung cancer: Based on a large cohort study. PLoS One.
10:e01264962015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Berardi R, Rinaldi S, Santoni M,
Newsom-Davis T, Tiberi M, Morgese F, Caramanti M, Savini A, Ferrini
C, Torniai M, et al: Prognostic models to predict survival in
patients with advanced non-small cell lung cancer treated with
first-line chemo- or targeted therapy. Oncotarget. 7:26916–26924.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yin Y, Wang J, Wang X, Gu L, Pei H, Kuai
S, Zhang Y and Shang Z: Prognostic value of the neutrophil to
lymphocyte ratio in lung cancer: A meta-analysis. Clinics (Sao
Paulo). 70:524–530. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sethi G, Shanmugam MK, Ramachandran L,
Kumar AP and Tergaonkar V: Multifaceted link between cancer and
inflammation. Biosci Rep. 32:1–15. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Candido J and Hagemann T: Cancer-related
inflammation. J Clin Immunol. 33 Suppl 1:S79–S84. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kumar V and Sharma A: Neutrophils:
Cinderella of innate immune system. Int Immunopharmacol.
10:1325–1334. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Borregaard N: Neutrophils, from marrow to
microbes. Immunity. 33:657–670. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Proctor MJ, Morrison DS, Talwar D, Balmer
SM, Fletcher CD, O'Reilly DS, Foulis AK, Horgan PG and McMillan DC:
A comparison of inflammation-based prognostic scores in patients
with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer.
47:2633–2641. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yu P and Fu YX: Tumor-infiltrating T
lymphocytes: Friends or foes? Lab Invest. 86:231–245. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kinoshita T, Muramatsu R, Fujita T, Nagumo
H, Sakurai T, Noji S, Takahata E, Yaguchi T, Tsukamoto N,
Kudo-Saito C, et al: Prognostic value of tumor-infiltrating
lymphocytes differs depending on histological type and smoking
habit in completely resected non-small-cell lung cancer. Ann Oncol.
27:2117–2123. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Inoue M, Okumura M, Sawabata N, Miyaoka E,
Asamura H, Yoshino I, Tada H, Fujii Y, Nakanishi Y, Eguchi K, et
al: Clinicopathological characteristics and surgical results of
lung cancer patients aged up to 50 years: The Japanese lung cancer
registry study 2004. Lung Cancer. 83:246–251. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Parsons A, Daley A, Begh R and Aveyard P:
Influence of smoking cessation after diagnosis of early stage lung
cancer on prognosis: Systematic review of observational studies
with meta-analysis. BMJ. 340:b55692010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kanarek NF, Hooker CM, Mathieu L, Tsai HL,
Rudin CM, Herman JG and Brock MV: Survival after community
diagnosis of early-stage non-small cell lung cancer. Am J Med.
127:443–449. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mak RH, Hermann G, Lewis JH, Baldini EH,
Chen AB, Colson YL, Hacker FH, Kozono D, Wee JO, Chen YH, et al:
Outcomes by tumor histology and KRAS mutation status after lung
stereotactic body radiation therapy for early-stage non-small-cell
lung cancer. Clin Lung Cancer. 16:24–32. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Trani L, Myerson J, Ashley S, Young K,
Sheri A, Hubner R, Puglisi M, Popat S and O'Brien ME: Histology
classification is not a predictor of clinical outcomes in advanced
non-small cell lung cancer (NSCLC) treated with vinorelbine or
gemcitabine combinations. Lung Cancer. 70:200–204. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yodying H, Matsuda A, Miyashita M,
Matsumoto S, Sakurazawa N, Yamada M and Uchida E: Prognostic
significance of Neutrophil-to-Lymphocyte ratio and
platelet-to-Lymphocyte ratio in oncologic outcomes of esophageal
cancer: A systematic review and meta-analysis. Ann Surg Oncol.
23:646–654. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wei B, Yao M, Xing C, Wang W, Yao J, Hong
Y, Liu Y and Fu P: The neutrophil lymphocyte ratio is associated
with breast cancer prognosis: An updated systematic review and
meta-analysis. Onco Targets Ther. 9:5567–5575. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Sun J, Chen X, Gao P, Song Y, Huang X,
Yang Y, Zhao J, Ma B, Gao X and Wang Z: Can the neutrophil to
lymphocyte ratio be used to determine gastric cancer treatment
outcomes? A systematic review and meta-analysis. Dis Markers.
2016:78624692016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Sun XD, Shi XJ, Chen YG, Wang CL, Ma Q and
Lv GY: Elevated preoperative Neutrophil-Lymphocyte ratio is
associated with poor prognosis in hepatocellular carcinoma patients
treated with liver transplantation: A meta-analysis. Gastroenterol
Res Pract. 2016:47438082016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Yang JJ, Hu ZG, Shi WX, Deng T, He SQ and
Yuan SG: Prognostic significance of neutrophil to lymphocyte ratio
in pancreatic cancer: A meta-analysis. World J Gastroenterol.
21:2807–2815. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Tsai PL, Su WJ, Leung WH, Lai CT and Liu
CK: Neutrophil-lymphocyte ratio and CEA level as prognostic and
predictive factors in colorectal cancer: A systematic review and
meta-analysis. J Cancer Res Ther. 12:582–589. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Hu K, Lou L, Ye J and Zhang S: Prognostic
role of the neutrophil-lymphocyte ratio in renal cell carcinoma: A
meta-analysis. BMJ Open. 5:e0064042015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Tang L, Li X, Wang B, Luo G, Gu L, Chen L,
Liu K, Gao Y and Zhang X: Prognostic value of
Neutrophil-to-Lymphocyte ratio in localized and advanced prostate
cancer: A systematic review and meta-analysis. PLoS One.
11:e01539812016. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Davis JL, Moutinho V Jr, Panageas KS and
Coit DG: A peripheral blood biomarker estimates probability of
survival: The neutrophil-lymphocyte ratio in noncancer patients.
Biomark Med. 10:953–957. 2016. View Article : Google Scholar : PubMed/NCBI
|
